From FDA labels and ClinicalTrials.gov

Are GLP-1s being studied for cancer?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists cancer as an approved use, so prescribing one for it would be off-label. Meta-analysis of 50 randomized trials (GLP-1s): On cancer risk rather than treatment: no significant difference overall (odds ratio 1.05). It saw a signal for thyroid cancer (1.55), more evident in longer trials, which the authors say needs further specific study. It also saw a small increase in colorectal cancer in shorter trials (1.27), which they say may reflect more diagnostic tests in people with stomach side effects. Diabetes Obes Metab, 2025 (pubmed.ncbi.nlm.nih.gov/40437949). ClinicalTrials.gov lists 30 trials of these medicines on it: 0 with posted results and 13 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 16, 2026.

Published results

What the largest trials on cancer found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Meta-analysis of 50 randomized trials

GLP-1s · On risk, not treatment · Meta-analysis

On cancer risk rather than treatment: no significant difference overall (odds ratio 1.05). It saw a signal for thyroid cancer (1.55), more evident in longer trials, which the authors say needs further specific study. It also saw a small increase in colorectal cancer in shorter trials (1.27), which they say may reflect more diagnostic tests in people with stomach side effects.

Diabetes Obes Metab, 2025 (pubmed.ncbi.nlm.nih.gov/40437949)

The registry

Trials on cancer, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Tirzepatide1408
Semaglutide1304
Exenatide101
Liraglutide100
Mazdutide100
Recruiting now

Trials on cancer taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors (clinicaltrials.gov/study/NCT07257484)TirzepatidePhase 4Feb 25, 2028
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium (clinicaltrials.gov/study/NCT06073184)SemaglutidePhase 2Feb 2032
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial (clinicaltrials.gov/study/NCT07202247)SemaglutidePhase 2Apr 9, 2028
Tirzepatide Weight Loss for MRD+ Early Breast Cancer (clinicaltrials.gov/study/NCT06517212)TirzepatidePhase 2Dec 31, 2030
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer (clinicaltrials.gov/study/NCT06518837)TirzepatidePhase 2Sep 30, 2027
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study (clinicaltrials.gov/study/NCT07874828)TirzepatidePhase 2Dec 31, 2036
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (clinicaltrials.gov/study/NCT07107334)SemaglutidePhase 2Nov 2029
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (clinicaltrials.gov/study/NCT05663515)ExenatideNot phasedOct 1, 2026
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study (clinicaltrials.gov/study/NCT06759701)TirzepatidePhase 1Dec 31, 2028
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib (clinicaltrials.gov/study/NCT07782359)TirzepatidePhase 1Jun 2030
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer (clinicaltrials.gov/study/NCT07627191)SemaglutidePhase 1Jun 30, 2028
Tirzepatide in Obesity-Driven Endometrial Cancer (clinicaltrials.gov/study/NCT07065552)TirzepatidePhase 1Jul 2028
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors (clinicaltrials.gov/study/NCT07095517)TirzepatidePhase 1Dec 31, 2028
From PubMed

Newest papers on GLP-1s and cancer

  • GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes (pubmed.ncbi.nlm.nih.gov/42942021)

    Systematic review · Int J Mol Sci · Oct 18, 2026 · Andronescu AC et al.

  • Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42600634)

    Meta-analysis · Horm Metab Res · Aug 14, 2026 · Zhong X et al.

  • Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials (pubmed.ncbi.nlm.nih.gov/42297743)

    Meta-analysis · Diabetes Obes Metab · Jun 15, 2026 · Chiang CH et al. · cited by 1

  • GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review (pubmed.ncbi.nlm.nih.gov/42215399)

    Systematic review · Dis Mon · May 29, 2026 · Parekh RS et al.

  • Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/41991368)

    Meta-analysis · Pancreatology · Apr 6, 2026 · Lauri G et al. · cited by 1

  • EPR26-152: GLP-1 and Dual Agonists and the Incidence of Skin Cancer: Evidence from Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42066808)

    Randomized trial · J Natl Compr Canc Netw · Mar 31, 2026 · Chang YC et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on cancer

  • TrialNew Semaglutide study registered: Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer (clinicaltrials.gov/study/NCT07909889)
  • TrialNew Tirzepatide study registered: PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study (clinicaltrials.gov/study/NCT07874828)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and cancer: common questions

What did the largest trial on cancer find?

Meta-analysis of 50 randomized trials (GLP-1s): On cancer risk rather than treatment: no significant difference overall (odds ratio 1.05). It saw a signal for thyroid cancer (1.55), more evident in longer trials, which the authors say needs further specific study. It also saw a small increase in colorectal cancer in shorter trials (1.27), which they say may reflect more diagnostic tests in people with stomach side effects.

Is any GLP-1 FDA approved for cancer?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for cancer?

Tirzepatide, with 14 registered trials on it, then Semaglutide with 13. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for cancer?

13 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.